Skip to main content

Abbott to Acquire Vysis for $355M

NEW YORK, Oct. 24 - Abbott Laboratories has agreed to acquire Vysis in a stock deal worth about $355 million in an attempt to buttress its position in the DNA-based diagnostic market, the drug giant announced on Wednesday.

Abbott will pay $30.50 per share for Vysis, which is a 33 percent premium on Vysis shares, the company said. Shares in the Downers Grove, Illinois-based company closed at $23 on the Nasdaq on Tuesday.

Vysis manufactures and markets two tests that detect certain genetic markers for breast and bladder cancer.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.